Keyphrases
Neuroblastoma
86%
High-risk Neuroblastoma
65%
Working Diagnosis
32%
Anti-GD2
27%
Tumor
25%
Interleukin-2
25%
Tumor Regression Rate
20%
TIGIT
20%
Rate Factor
20%
Stage 4S
20%
Ganglioneuroblastoma
20%
Chronic Course
20%
Bone Metastasis
20%
Neuroblastoma Cancer
20%
Cancer Cells
20%
Regulatory Immune Response
20%
Nectin-2
20%
Single-cell RNA Sequencing (scRNA-seq)
20%
Integrative Analysis
20%
Netherlands
20%
Increased Incidence
20%
Late Events
20%
Patient Cohort
20%
Risk Factors
20%
Progressive Disease
20%
Disease Course
20%
Immune Monitoring
20%
Event-free Survival
20%
Improved Survival
20%
Granulocyte Colony-stimulating Factor (G-CSF)
17%
Catecholamines
15%
Clinical Course
15%
Natural Killer Cells
13%
High-dose Chemotherapy
10%
Liver Size
10%
Immunomodulatory
10%
Tumor Regression
10%
123I-MIBG
10%
Complete Response
10%
Maintenance Therapy
10%
Dutch
10%
Primary Tumor
10%
Average Annual Percentage Change
10%
Anti-GD2 Antibody
10%
Isotretinoin
10%
Immunotherapeutics
9%
T Cells
9%
5-year OS
8%
Age at Diagnosis
8%
Immune Enhancement
8%
Medicine and Dentistry
Ganglioneuroblastoma
100%
Immunotherapy
45%
Disease
31%
RNA Sequence
20%
Tumor Regression
20%
Bone Metastasis
20%
Progressive Disease
20%
Messenger RNA
20%
Event Free Survival
13%
Disease Course
12%
Catecholamine Excretion
10%
Catecholamine
10%
Neoplasm
9%
Programmed Death-Ligand 1
8%
T Cell
8%
Chemotherapy
8%
Urinary System
7%
Primary Tumor
7%
Isotretinoin
6%
Maintenance Therapy
6%
Iodine 123
5%
Stem Cell
5%
High Dose Chemotherapy
5%
(3 Iodobenzyl)guanidine
5%
Fatality
5%
Liver Metastasis
5%
Retrospective Cohort Study
5%
Treatment Response
5%
Overall Survival
5%
